2.97
1.37%
0.04
Tscan Therapeutics Inc Stock (TCRX) Forecast
The Tscan Therapeutics Inc (TCRX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $2.9325, representing a -1.26% decrease from the current price of $2.97. The highest analyst price target is $3.5292, and the lowest is $2.3359.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month TCRX Price Target
Average 3.7515
(+26.31% Upside)
Is Tscan Therapeutics Inc (TCRX) A Buy Now?
Oscillators
Name | Value | Action |
---|---|---|
RSI(14) | 31.18 | Neutral |
STOCH(9,6) | 15.22 | Buy |
STOCHRSI(14) | 20.10 | Neutral |
MACD(12,26) | -0.5234 | Sell |
ADX(14) | 34.39 | Sell |
William %R | -83.56 | Buy |
CCI(14) | -60.93 | Neutral |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
Period | Simple | Exponential |
---|---|---|
MA10 |
3.17
Sell
|
3.2294
Sell
|
MA20 |
3.8575
Sell
|
3.6594
Sell
|
MA50 |
4.578
Sell
|
4.3696
Sell
|
MA100 |
5.1083
Sell
|
5.0127
Sell
|
MA200 |
6.3138
Sell
|
5.317
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, TCRX could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 12 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on TCRX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 31.18 indicates that TCRX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 15.22 indicates that TCRX is oversold. This indicates that TCRX price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 20.1 indicates that TCRX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 34.39 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -60.93 indicates that TCRX is still oversold but not to an extreme extent.
Long-term TCRX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Tscan Therapeutics Inc financial reports and earnings history, Tscan Therapeutics Inc (TCRX) stock could reach $7.7587 by 2030, $7.3728 by 2040 and $10.08 by 2050. See the projected annual prices until 2050 of the Tscan Therapeutics Inc stock below:
- Tscan Therapeutics Inc (TCRX) is expected to reach an average price of $5.7288 in 2035, with a high prediction of $6.4321 and a low estimate of $5.5688. This indicates an $92.89% rise from the last recorded price of $2.97.
- Tscan Therapeutics Inc (TCRX) stock is projected to chart a bullish course in 2040, with an average price target of $6.8578, representing an $130.90% surge from its current level. The forecast ranges from a conservative $6.7011 to a sky-high $7.3728.
- Our analysts predict Tscan Therapeutics Inc (TCRX) to jump 252.41% by 2045, soaring from $10.09 to an average price of $10.47, potentially reaching $11.62. While $10.09 is the low estimate, the potential upside is significant.
- Tscan Therapeutics Inc (TCRX) stock is expected to climb by 2050, reaching an average of $9.7535, a $228.40% jump from its current level. However, a wide range of estimates exists, with high and low targets of $10.08 and $8.4776, respectively, highlighting the market's uncertainty.
Tscan Therapeutics Inc Stock (TCRX) Year by Year Forecast
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2025
Tscan Therapeutics Inc Stock (TCRX) is expected to reach an average price of $3.7515 in 2025, with a high prediction of $5.3013 and a low estimate of $2.2018. This indicates an +26.31% rise from the last recorded price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2025 | $3.2259 | $2.3359 | $3.5292 | +8.62% |
February, 2025 | $3.7876 | $3.1863 | $4.4763 | +27.53% |
March, 2025 | $3.8842 | $3.4718 | $4.308 | +30.78% |
April, 2025 | $4.9713 | $3.7597 | $5.3013 | +67.38% |
May, 2025 | $3.733 | $3.363 | $5.1517 | +25.69% |
June, 2025 | $3.6647 | $3.4238 | $5.0042 | +23.39% |
July, 2025 | $3.6267 | $3.3651 | $4.3967 | +22.11% |
August, 2025 | $3.5084 | $3.2484 | $4.0572 | +18.13% |
September, 2025 | $3.0084 | $2.8197 | $3.6387 | +1.29% |
October, 2025 | $2.6422 | $2.2018 | $3.1905 | -11.04% |
November, 2025 | $2.5739 | $2.4026 | $3.4234 | -13.34% |
December, 2025 | $3.7059 | $2.4401 | $4.0355 | +24.78% |
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2026
The predicted value for Tscan Therapeutics Inc (TCRX) in 2026 is set at an average of $5.1522. Estimates vary from a peak of $7.9243 to a trough of $2.3801, indicating an +73.48% surge from the present price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2026 | $3.0776 | $3.0376 | $4.1618 | +3.62% |
February, 2026 | $3.2293 | $2.6789 | $3.5379 | +8.73% |
March, 2026 | $3.961 | $2.3801 | $6.7904 | +33.37% |
April, 2026 | $3.4731 | $2.7214 | $4.1026 | +16.94% |
May, 2026 | $2.8747 | $2.6947 | $3.7735 | -3.21% |
June, 2026 | $2.9264 | $2.8356 | $3.155 | -1.47% |
July, 2026 | $3.2285 | $2.6968 | $3.3385 | +8.70% |
August, 2026 | $3.3302 | $3.1189 | $3.8057 | +12.13% |
September, 2026 | $4.6222 | $3.2006 | $5.0172 | +55.63% |
October, 2026 | $5.8939 | $4.3227 | $6.1639 | +98.45% |
November, 2026 | $5.7256 | $5.5756 | $7.9243 | +92.78% |
December, 2026 | $6.1677 | $5.366 | $6.9568 | +107.67% |
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Tscan Therapeutics Inc (TCRX) is $7.2809, with a high forecast of $10.80 and a low forecast of $3.7659. This indicates an +145.15% increase from the last price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2027 | $6.5894 | $5.4181 | $6.9794 | +121.86% |
February, 2027 | $7.981 | $6.2198 | $8.6502 | +168.72% |
March, 2027 | $7.8731 | $7.1814 | $9.7827 | +165.09% |
April, 2027 | $8.5048 | $7.3639 | $8.9035 | +186.36% |
May, 2027 | $10.07 | $7.60 | $10.08 | +239.11% |
June, 2027 | $10.09 | $7.6134 | $10.80 | +239.59% |
July, 2027 | $9.1092 | $9.0792 | $10.75 | +206.71% |
August, 2027 | $6.3125 | $5.9825 | $9.14 | +112.54% |
September, 2027 | $6.3067 | $5.6351 | $6.9034 | +112.35% |
October, 2027 | $6.4301 | $5.9601 | $7.0561 | +116.50% |
November, 2027 | $5.4634 | $5.0634 | $6.4959 | +83.95% |
December, 2027 | $3.7676 | $3.7659 | $5.3542 | +26.85% |
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2028
In 2028, Tscan Therapeutics Inc (TCRX) is projected to reach an average price of $4.4981, with a high projection of $6.0426 and a low estimate of $2.9535. This indicates an +51.45% rise from the last price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2028 | $3.2709 | $3.1209 | $4.2634 | +10.13% |
February, 2028 | $4.6743 | $3.0718 | $5.2126 | +57.38% |
March, 2028 | $4.6235 | $4.2097 | $5.0459 | +55.67% |
April, 2028 | $4.8318 | $4.4994 | $5.2818 | +62.69% |
May, 2028 | $4.476 | $4.106 | $6.0426 | +50.71% |
June, 2028 | $4.4093 | $4.1676 | $5.7485 | +48.46% |
July, 2028 | $4.4927 | $4.1102 | $4.976 | +51.27% |
August, 2028 | $4.2568 | $3.9968 | $5.1435 | +43.33% |
September, 2028 | $3.7585 | $3.5694 | $4.3876 | +26.55% |
October, 2028 | $3.0535 | $2.9535 | $3.941 | +2.81% |
November, 2028 | $3.3277 | $3.1044 | $4.1769 | +12.04% |
December, 2028 | $4.5011 | $3.1948 | $4.7911 | +51.55% |
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2029
The 2029 price forecast for Tscan Therapeutics Inc Stock (TCRX) is $5.9195 on average, with a high prediction of $8.6987 and a low estimate of $3.1402. This represents an +99.31% increase from the previous price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2029 | $3.8352 | $3.7952 | $4.9186 | +29.13% |
February, 2029 | $3.9886 | $3.4377 | $4.296 | +34.30% |
March, 2029 | $4.7219 | $3.1402 | $7.551 | +58.99% |
April, 2029 | $4.3944 | $3.4828 | $4.8653 | +47.96% |
May, 2029 | $3.6394 | $3.4594 | $4.5591 | +22.54% |
June, 2029 | $3.6928 | $3.6011 | $3.9202 | +24.34% |
July, 2029 | $3.9161 | $3.4636 | $4.0661 | +31.86% |
August, 2029 | $4.1003 | $3.8761 | $4.5755 | +38.06% |
September, 2029 | $4.9437 | $3.9711 | $5.4328 | +66.45% |
October, 2029 | $6.6678 | $4.9445 | $6.9378 | +124.51% |
November, 2029 | $6.5012 | $6.3512 | $8.6987 | +118.89% |
December, 2029 | $7.5545 | $6.142 | $7.7337 | +154.36% |
Tscan Therapeutics Inc Stock (TCRX) Price Forecast for 2030
Tscan Therapeutics Inc Stock (TCRX) is expected to reach an average price of $8.2304 in 2030, with a high forecast of $11.52 and a low forecast of $4.942. This signifies an +177.12% surge from the last price of $2.97.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2030 | $7.3687 | $6.1962 | $7.7587 | +148.10% |
February, 2030 | $8.762 | $6.9995 | $9.4304 | +195.02% |
March, 2030 | $9.5054 | $7.9629 | $10.57 | +220.05% |
April, 2030 | $8.8887 | $8.1479 | $9.7212 | +199.28% |
May, 2030 | $10.79 | $8.32 | $10.80 | +263.38% |
June, 2030 | $10.72 | $8.3351 | $11.46 | +260.86% |
July, 2030 | $9.8338 | $9.8038 | $11.52 | +231.10% |
August, 2030 | $7.0388 | $6.7088 | $9.865 | +137.00% |
September, 2030 | $6.7938 | $6.3622 | $7.6301 | +128.75% |
October, 2030 | $7.1601 | $6.5152 | $7.7857 | +141.08% |
November, 2030 | $6.1951 | $5.7951 | $7.2263 | +108.59% |
December, 2030 | $5.0901 | $4.942 | $6.0864 | +71.38% |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):